Regeneron

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Regeneron 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About REGN

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. 

CEO
Leonard S. Schleifer
CEOLeonard S. Schleifer
Employees
15,106
Employees15,106
Headquarters
Tarrytown, New York
HeadquartersTarrytown, New York
Founded
1988
Founded1988
Employees
15,106
Employees15,106

REGN Key Statistics

Market cap
58.56B
Market cap58.56B
Price-Earnings ratio
14.00
Price-Earnings ratio14.00
Dividend yield
0.32%
Dividend yield0.32%
Average volume
857.52K
Average volume857.52K
High today
$552.00
High today$552.00
Low today
$541.50
Low today$541.50
Open price
$550.00
Open price$550.00
Volume
1.31M
Volume1.31M
52 Week high
$1,211.20
52 Week high$1,211.20
52 Week low
$476.49
52 Week low$476.49

REGN News

TipRanks 8h
Regeneron and Sanofi’s Dupilumab Study: A Potential Breakthrough in Eosinophilic Gastritis Treatment

Regeneron Pharmaceuticals ((REGN)), Sanofi SA ((SNY)), Sanofi ((DE:SNW)), Sanofi ((SNYNF)) announced an update on their ongoing clinical study. Elevate Your In...

TipRanks 2d
Regeneron Advances Melanoma Treatment with New Phase 2 Trial

Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at...

TipRanks 3d
Regeneron and Sanofi’s Phase 3 Study on Itepekimab: A Potential Game-Changer for CRSwNP

Regeneron Pharmaceuticals ((REGN)), Sanofi SA ((SNY)), Sanofi ((DE:SNW)), Sanofi ((SNYNF)) announced an update on their ongoing clinical study. Elevate Your In...

Analyst ratings

70%

of 27 ratings
Buy
70.4%
Hold
25.9%
Sell
3.7%

More REGN News

Simply Wall St 7d
Accelerated FDA Approval of Lynozyfic May Change the Case for Investing in Regeneron

Regeneron Pharmaceuticals recently received accelerated FDA approval for Lynozyfic (linvoseltamab-gcpt) to treat adults with relapsed or refractory multiple mye...

Accelerated FDA Approval of Lynozyfic May Change the Case for Investing in Regeneron

People also own

Based on the portfolios of people who own REGN. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.